CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
CytomX Therapeutics, Inc. reported first-quarter 2026 results showing lower collaboration revenue and a return to net loss while strengthening its balance sheet. Revenue was $10.3 million, down from $50.9 million a year earlier, mainly due to completed and terminated collaborations with Bristol Myers Squibb, Amgen and Astellas.
The company recorded a net loss of $18.2 million, compared with net income of $23.5 million in the prior-year quarter, as revenue fell while research and development and general and administrative expenses remained roughly stable at $19.2 million and $10.7 million, respectively. Varseta-M (EpCAM ADC) was the largest R&D spend at $7.8 million, reflecting its role as the lead program.
CytomX raised significant capital through a March 2026 underwritten offering, issuing 45.99 million shares and 1.18 million pre-funded warrants for $234.2 million in net proceeds. As of March 31, 2026, it held $28.8 million in cash and cash equivalents and $317.9 million in short-term U.S. Treasury investments, giving total assets of $359.4 million and stockholders’ equity of $319.9 million.
CytomX Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. Proposals include electing two Class II directors, ratifying Ernst & Young LLP as auditor, and amending the charter to increase authorized common stock from 300,000,000 to 600,000,000 shares.
Stockholders are also asked to approve adding 6,500,000 shares to the 2015 Equity Incentive Plan and 1,000,000 shares to the Employee Stock Purchase Plan, plus advisory votes on executive pay and the frequency of future say‑on‑pay votes. Only holders of 217,702,919 shares outstanding as of April 20, 2026 may vote.
CytomX Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on June 17, 2026 with a record date of April 20, 2026. The meeting agenda includes seven proposals: election of two Class II directors (Matthew P. Young and Elaine V. Jones, Ph.D.), ratification of Ernst & Young LLP as auditor, a Charter Amendment to increase authorized common stock from 300,000,000 to 600,000,000, an increase of 6,500,000 shares to the Amended and Restated 2015 Equity Incentive Plan, and a 1,000,000 share increase to the Employee Stock Purchase Plan (ESPP). The proxy materials state 217,693,878 shares outstanding and 82,306,122 authorized but unissued common shares as of March 31, 2026. The Board recommends votes "For" all proposals.
CytomX Therapeutics reports a Schedule 13G showing Point72-affiliated holders beneficially own 10,864,581 shares of Common Stock, representing 5.0% of the class as of the close of business on April 15, 2026. The filing states the 216,177,309 shares outstanding figure is the sum of 45,990,567 shares issued in a March 18, 2026 offering and 170,186,742 shares outstanding as of February 28, 2026.
The statement is filed jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a Joint Filing Agreement and cites shared voting and dispositive power over the reported shares.
CytomX Therapeutics Inc schedule amendment shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% ownership as of 03/13/2026. The filing explains an internal realignment at The Vanguard Group that caused disaggregated reporting by subsidiaries.
CytomX Therapeutics Chief Medical Officer Yu‑Waye Chu reported an open-market sale of 21,279 shares of common stock at $6.423 per share. According to the filing, the shares were sold solely to cover tax and other government withholding obligations tied to vesting restricted stock units. After this transaction, Chu directly holds 189,446 shares, which includes 149,833 RSUs that may settle in stock as they vest.
CytomX Therapeutics CEO Sean A. McCarthy reported a tax-driven share sale. He sold 118,969 shares of common stock on March 17, 2026 at an average price of $6.423 per share, solely to satisfy tax and other government withholding obligations linked to vesting restricted stock units.
After this transaction, he directly holds 1,078,922 common shares, which include 457,500 RSUs, and indirectly holds 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee. The filing shows no remaining derivative securities such as stock options or warrants.
CytomX Therapeutics, Inc. executive Marcia Belvin, SVP and Chief Scientific Officer, reported an open-market sale of 31,492 shares of common stock on March 17, 2026 at $6.423 per share. The sale was made solely to satisfy tax or other government withholding obligations tied to vesting restricted stock units (RSUs).
After this transaction, Belvin directly holds 300,760 shares of common stock, which includes 135,833 RSUs. This filing reflects a compensation-related tax obligation rather than a discretionary portfolio trade.
CytomX Therapeutics, Inc. Chief Financial Officer Christopher Ogden sold 19,323 shares of common stock at an average price of $6.423 per share. The sale was made solely to satisfy tax and other government withholding obligations related to vesting restricted stock units. After this transaction, he directly holds 296,948 shares of common stock, which includes 173,082 restricted stock units.
CytomX Therapeutics completed an underwritten equity financing built around a large common stock and warrant sale. The company issued 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 per warrant, with underwriters holding a 30-day option to buy up to 7,075,471 additional shares at the public price.
The transaction closed on March 19, 2026 and is expected to generate approximately $234.4 million in net proceeds after underwriting discounts and expenses. CytomX plans to use the cash to continue developing Varseta-M, advance other pipeline programs, and for general corporate and working capital purposes.